At the upcoming 66th edition of the American Society of Hematology’s Annual Meeting & Exposition and the 2024 San Antonio Breast Cancer Symposium, Novartis plans to unveil insights from over 65 abstracts, encompassing numerous investigator-led studies.
“By emphasizing research in areas with critical unmet needs and focusing on earlier disease stages, our goal is to revolutionize treatment approaches for individuals who demand alternative therapeutic strategies,” commented Jeff Legos, the Executive Vice President and Global Head of Oncology Development at Novartis. “The novel findings to be showcased at ASH and SABCS reinforce our dedication to individuals afflicted with cancer or hematological disorders, complementing new and expanded indications for Scemblix and Kisqali, alongside the latest updates in national treatment standards.”
Beyond spotlighting pivotal data, Novartis is set to host an art gallery-style display at SABCS. This features heartfelt letters and stories penned by breast cancer survivors, offering a raw, genuine glimpse into their journeys. The narratives aim to inspire patients, foster introspection, and demonstrate the resilience and community within the breast cancer sphere.
**Highlighted abstracts enlisted by ASH include:**
– **Scemblix:** Asciminib highlights its superior safety profile against each investigator-selected Tyrosine Kinase Inhibitor for newly diagnosed Chronic Myeloid Leukemia patients in Phase 3 ASC4FIRST study — Abstract #475 – Oral Presentation – December 8, 9:30 – 11:00 AM PT.
– **Scemblix:** Demonstrating efficacy and safety in Chronic Myeloid Leukemia, interim Phase 2 ASC2ESCALATE results offer insight post one prior TKI treatment — Abstract #479 – Oral Presentation – December 8, 9:30 – 11:00 AM PT.
– **Scemblix:** Asciminib proves highly effective in ongoing Chronic Phase Chronic Myelogenous Leukemia treatment at specific dosages in ASC4OPT study — Abstract #4526 – Poster Presentation – December 9, 6:00 – 8:00 PM PT.
– **Scemblix:** Asciminib’s efficacy as a second-line treatment post a prior TKI reviewed in a U.S. chart study — Abstract #3812 – Poster Presentation – December 8, 6:00 – 8:00 PM PT.
– **Ianalumab (VAY736):** Phase 2 insights on primary immune thrombocytopenia patients treated with Ianalumab after two prior therapies — Abstract #710 – Oral Presentation – December 9, 10:30 AM – 12:00 PM PT.
– **Rapcabtagene autoleucel (YTB323):** Updated clinical outcomes for relapsed/refractory Diffuse Large B-Cell Lymphoma patients in Phase II study — Abstract #67 – Oral Presentation – December 7, 9:30 – 11:00 AM PT.
– **Fabhalta:** Oral Iptacopan shows long-term benefits on quality of life and treatment signs for Paroxysmal Nocturnal Hemoglobinuria — Abstract #4079 – Poster Presentation – December 9, 6:00 – 8:00 PM PT.
– **Fabhalta:** Hematological consistency in Iptacopan’s effect regardless of previous anti-C5 treatments in PNH patients — Abstract #4087 – Poster Presentation – December 9, 6:00 – 8:00 PM PT.
– **Fabhalta:** Initial data from app-based reports study assessing disease burden in PNH show key patient characteristics — Abstract #2327 – Poster Presentation – December 7, 5:30 – 7:30 PM PT.
– **Pelabresib (CPI-0610):** Latest results from Phase 3 Manifest-2 Pelabresib-ruxolitinib combination for myelofibrosis reveal updated insights — Abstract #3178 – Poster Presentation – December 8, 6:00 PM – 8:00 PM PT.
***Key abstracts from SABCS involve:***
– **Kisqali (ribociclib):** Analyzing risk-free survival in key subgroups for early breast cancer from phase 3 NATALEE trial — Abstract #P4-09-22 – Poster Session – December 12, 5:30 – 7:30 PM CST.
– **Kisqali:** Evaluating ribociclib dose modification’s impact on early breast cancer patients in NATALEE — Abstract #P1-11-16 – Poster Session – December 11, 12:30 – 2:00 PM CST.
– **Kisqali:** Studying recurrence risk patterns in real-world NATALEE and monarchE patients via health record analyses — Abstract #P2-12-02 – Poster Session – December 11, 5:30 – 7:00 PM CST.
– **Kisqali:** Tolerability insights from first-line ribociclib treatment for metastatic breast cancer across dual U.S. datasets — Abstract #P3-10-14 – Poster Session – December 12, 12:30 – 2:00 PM CST.
– **Kisqali:** Investigating ribociclib efficacy and safety influenced by body mass index in advanced breast cancer — Abstract #P2-09-20 – Poster Session – December 11, 5:30 – 7:00 PM CST.
– **Kisqali:** Comparative analysis of ribociclib + endocrine therapy against combination chemotherapy in aggressive HR+ HER2- advanced breast cancer — Abstract #PS2-06 – Poster Presentation – December 12, 7:00 – 8:30 AM CST.
As a pioneering medicines enterprise, Novartis commits to reshaping medical paradigms to enhance and prolong patient lives, thereby empowering patients, healthcare professionals, and communities globally. Their medicinal reach spans over 250 million individuals globally.